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Abstract 
Cumulative evidence now suggests that the abnormal 
aggregation of the neuronal protein alpha-synuclein is 
critically involved in the pathogenesis of synucleinopathies, 
of which Parkinson’s disease (PD) is the most prevalent. 
Development of neuropathology appears to be linked to 
events that accelerate the rate of aggregation of alpha-
synuclein from monomers, via soluble oligomeric 
intermediates, into amyloid fibrils. Although increasing 
data suggest that oligomeric aggregates, not amyloid fibrils, 
disrupt or permeabilise cellular membranes, the nature of 
the neurotoxic species and its precise molecular 
mechanism still remain largely unknown, hampering the 
development of an effective treatment for the disease. 
Currently, there is no approved therapeutic agent directed 
toward preventing alpha-synuclein aggregation and only 
symptomatic therapies are available with a limited time-
frame of utility. Numerous studies have demonstrated the 
protective effects of dietary polyphenols against neuronal 
damage in PD. 
The aim of this review is to look at what research has 
been done so far to show that dietary polyphenolic 
compounds can effectively interfere with alpha-synuclein 
oligomerisation. Evidence in the role and mechanisms of 
diet-derived phenolic products may guide the design of 
novel therapeutic drugs that can block early stages of 
amyloid self-assembly in PD and related synucleinopathies. 
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Introduction 
Parkinson’s Disease (PD) is the most common 
movement disorder and following Alzheimer’s 
Disease (AD), the second most frequent progressive 
neurodegenerative disease.1 PD affects approximately 
1% of the population over the age of 50 with classical 
clinical manifestations of tremors, bradykinesia, 
muscle rigidity, and akinesia.2,3 In its etiology, PD is 
shown to be multifactorial, with underlying genetic 
susceptibility in some cases and environmental factors 
predominating in other instances.4 The 
neuropathological hallmarks of PD are characterized 
by progressive and profound loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc) 
with the presence of Lewy bodies (LBs) and Lewy 
neurites (LNs).5 Although the precise mechanism of 
pathogenesis remains hotly debated, there is strong 
evidence implicating increased expression of alpha-
synuclein and pathologically altered forms of this 
protein in the pathophysiology of both familial and 
sporadic PD, culminating in a loss of dopaminergic 
neurons.6 
A substantial amount of in vitro and in vivo studies 
have demonstrated the protective effects of 
polyphenols, either as single compounds (e.g. 
epigallocatechine-gallate [EGCG]) or extracts (grape, 
blueberry, and green tea), against neuronal damage in 
PD.7 Data exists showing that these phenolic 
compounds can target specific signaling pathways and 
interact with specific proteins, including aggregation 
of alpha-synuclein.8,9,10 In this review, the implication 
of alpha-synuclein aggregation in the pathogenesis of 
PD and how dietary polyphenols have been shown to 
inhibit such aggregation will be appraised.  
 
Mediators of alpha-synuclein toxicity in biological 
systems 
Alpha-synuclein, a small (~14 kDa), highly acidic 
soluble protein is abundantly expressed throughout the 
CNS and widely distributed throughout the brain 
particularly in the neocortex, hippocampus, striatum, 
thalamus and cerebellum where it constitutes about 
0.5-1.0% of the entire cytosolic protein content.11,12 
Although the physiological function/s of alpha-
synuclein in normal neurons remains to be established, 
it has been implicated in the regulation of synaptic 
plasticity and membrane stability at the presynaptic 
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level, neuronal differentiation, regulation of dopamine 
synthesis, release or storage and protein networks.13,14,15 
The study of protein aggregation saw a new start in the last 
decade, when it was discovered that protein misfolding 
and aggregation is the most likely cause of several human 
diseases such as neurological and systemic diseases.16 A 
characteristic of protein-misfolding diseases is the fact that 
soluble monomeric proteins are progressively folded into 
insoluble, filamentous polymers which accumulate in a 
disease/protein-specific manner, either as fibrillar amyloid 
deposits in the cytosol (‘inclusions’), or in the extracellular 
space (‘plaques’).17 The simple overproduction of wild-
type alpha-synuclein may account for aggregation that 
requires a minimum concentration of the monomer. Indeed, 
multiplication and mutations of the alpha-synuclein gene 
are associated with different phenotypes of PD, most likely 
resulting from an enhanced alpha-synuclein monomer 
level.18 Substantial evidence exists showing that 
overexpression of human alpha-synuclein in various 
mammalian cells and animal models can cause apoptosis, 
damage cell organelles and enhance susceptibility to 
oxidative stress in the absence of detectable fibril 
formation.19 
The roles of the various physical forms (i.e. monomers, 
oligomers or fibrils) of alpha-synuclein in PD pathogenesis 
remains controversial. A minority of researchers consider 
LBs to be neurotoxic, while most others deem them to be 
protective.20,21 Although the cause of neurodegeneration in 
PD is not fully understood, substantial data from in vitro 
and in vivo studies supports the hypothesis that small 
alpha-synuclein oligomeric aggregates (rather than the 
fibrillar amyloid deposits or the LBs) represent the 
principal pathogenic species.22,23 It has been shown that 
alpha-synuclein soluble oligomeric forms share a common 
structure with other amyloidogenic proteins, such as 
amylin, insulin, prion protein etc. implying a common 
mechanism of pathogenesis.24 There is increasing evidence 
that these oligomers are critical species in the early stages 
of most, if not all, pathological aggregation and especially 
fibrillation reactions.25 A possible mechanism of toxicity 
by these transient oligomers of alpha-synuclein has been 
proposed showing that these oligomers can form structures 
with pore-like morphologies and that these pore-like 
structures contribute to cytotoxicity in neurodegenerative 
diseases by disrupting organelle membranes and hence 
their function.26 Many studies have recently focused on the 
relationship between alpha-synuclein aggregation and 
mitochondrial dysfunction, which is a defect occurring 
early in the pathogenesis of both sporadic and familial 
PD.27 Alpha-synuclein aggregates have been proposed to 
form pores in mitochondria leading to mitochondrial 
dysfunction and enhanced oxidative stress conditions. 28 
Thus, drugs and genetic approaches with the potential to 
inhibit alpha-synuclein aggregation and adjust 
mitochondrial dynamics, function and biogenesis may help 
in attenuating the onset of PD. 
 
Inhibition of alpha-synuclein toxicity by polyphenols 
In PD, only symptomatic treatment is available at the 
moment, mainly by elevating dopamine levels through the 
administration of L-DOPA (L-3,4-
dihydroxyphenylalanine; Levodopa) in combination 
with a peripheral L-DOPA decarboxylase inhibitor.29 
Currently, no disease-modifying drug therapy is 
available for PD, which aims to slow or halt the 
progression of neuronal death.30 Alpha-synuclein’s 
propensity to misfold and accumulate as cytoplasmic 
aggregates led to the hypothesis that toxicity could be 
prevented by interfering with the process of misfolding 
and aggregation.31 Besides caffeine and vitamins, 
aromatic-rich polyphenolic compounds from green tea, 
wine and other dietary food, are supposed to have a 
preventive or attenuating effect on PD progression.32 
Polyphenolic compounds are naturally-present 
constituents of a wide variety of fruits, vegetables, 
food products and beverages derived from plants such 
as olive oil, tea, and red wine. In the last decade, there 
has been a surge in interest on polyphenols, as several 
epidemiological studies revealed that these compounds 
can promote health and protect from several chronic 
diseases such as cancers, cardiovascular and 
neurodegenerative diseases.33,34 Overall, there is 
emerging evidence from cultured human cell lines and 
animal studies that polyphenols may potentially have a 
protective effect against the development of 
neurodegenerative diseases and may improve 
cognitive function in patients with established 
neurodegenerative diseases.35  
It has been argued that three important aspects 
need to be taken in consideration when making health 
claims with confidence regarding polyphenols: (i) 
biovailablity, (ii) epidemiological studies that 
investigated polyphenol-rich foods rather than pure 
polyphenol preparations, and (iii) that it is extremely 
difficult to estimate with any degree of precision the 
amount of polyphenols needed for potential health 
benefits in humans, based on concentrations used in 
vitro and animal studies.36 Although these are valid 
points to take into consideration, recent studies have 
shown that polyphenols can be bioavailable and cross 
the blood-brain barrier. For example, oral 
administration of the phenolic compound 
nordihydroguaiaretic acid (NDGA) in mice was 
successful in modulating amyloid aggregation 
pathways in vivo and prevented the development of 
AD neuropathology.37 It was also shown that grape-
derived polyphenolics do reach the brain and that 
systemic oral bioavailability of EGCG in rats can be 
increased more than twofold by formation and 
administration of nanolipidic EGCG particles.38,39 
Such strategies may allow polyphenols to achieve 
therapeutically effective concentrations in clinical 
settings. 
The precise mechanisms by which polyphenols 
exert their beneficial actions remain unclear. Recent 
studies have hypothesized that their classical 
hydrogen-donating antioxidant activity is unlikely to 
be the only explanation for cellular effects.40 It was 
further suggested that alterations in membrane and 
protein functions can occur at very low polyphenol 
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concentrations, and still have major effects on biological 
events.33 Thus, protein-polyphenol interactions can be 
relevant at concentrations much lower than those 
necessary to cope with a constant free radical production. 
Therefore, a direct action of polyphenols on protein 
aggregation is a very probable mechanism of the 
compound’s action in vivo. In fact, a survey of the current 
literature shows convincing evidence of the protective 
effect of polyphenols against amyloid cytotoxicity from in 
vitro to human studies. In order to better elucidate the 
mechanisms by which these polyphenols are acting, it is 
pertinent to briefly look at the striking property of these 
compounds to prevent and destabilize the formation of 
toxic amyloidogenic proteins. 
 
Effects of polyphenols on alpha-synuclein aggregation  
During the past decade, a significant number of in 
vitro assays investigated the direct effect of certain 
polyphenols on amyloid fibril formation, with a select 
number of polyphenols shown to efficiently inhibit and 
destabilize amyloidogenic fibrillation.41,42 Other data also 
demonstrated that several polyphenols counteract the 
cytotoxic properties of alpha-synuclein aggregates directly 
in a cellular context.43 EGCG, the most abundant 
polyphenolic extract from green tea, has recently attracted 
much research interest in the field of protein-misfolding 
diseases because of its potent anti-amyloid-fibril effect. 
EGCG was demonstrated to efficiently inhibit fibril 
formation of alpha-synuclein.44,45 Specifically, it was 
shown that EGCG transforms large alpha-synuclein fibrils 
into smaller non-toxic, amorphous protein aggregates 
which do not cause a quantitative release of monomers or 
small oligomers that subsequently reassemble into larger 
protein aggregates.46 More recently, it was found that a 
group of polyphenols exhibited potent dose-dependent 
inhibitory activity on alpha-synuclein aggregation.9 
Among the most promising polyphenols tested were green 
tea extract, resveratrol, catechines, baicalein and tannic 
acid.47 Thus, polyphenols with anti-aggregation properties 
appear to be potential key molecules for the development 
of preventives and therapeutics for PD and related 
synucleinopathies. 
 
Conclusion 
It is increasingly evident from published studies that 
misfolded and aggregated disease proteins are not simply 
neuropathologic markers of neurodegenerative disorders 
but, instead, they almost certainly contribute to disease 
pathogenesis. Thus paving the way for the identification of 
rational therapeutic agents designed to inhibit or reverse 
the fibrillation and aggregation of alpha-synuclein in PD 
could have potential disease-modifying effects. 
Polyphenolic compounds have been shown to regulate the 
toxic effects of aggregated proteins such as alpha-
synuclein. Detailed investigations into the mechanisms of 
natural phenolic products may guide the design of novel 
therapeutic drugs in PD which possess enhanced properties 
in vivo (e.g. ability to penetrate the blood-brain barrier), 
but which retain the bioactivity characteristic of the 
natural product scaffold. This insight in turn will offer 
prospects for identifying inhibitors such as 
polyphenols aimed at arresting and/or reversing the 
progression of PD and related synucleinopathies. 
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